Investigational drug · Phase 2
ER2001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Huntington Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ER2001"
First trial start
2025
Feb 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ER2001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Huntington Disease
Approved drugs for the same conditions: Huntington's disease chorea · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "ER2001" as an intervention, largest first.
- A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.Active, not recruiting
ExoRNA BioscienceIndustry
NCT07339514 · 27 participants (planned) · Start Feb 11, 2025 · Primary completion Apr 1, 2026
Drug: ER2001 intravenous injection; Placebo · For: Huntington Disease
Sites: Guangzhou, China; Chengdu, China · 3 sites in all
ExoRNA BioscienceIndustry
NCT06024265 · 10 participants · Start Apr 4, 2023 · Primary completion Jan 31, 2025
Drug: ER2001 injection · For: Huntington Disease
Sites: Guangzhou, China
ExoRNA BioscienceIndustry
NCT07344519 · 8 participants · Start Jun 25, 2024 · Primary completion Jun 1, 2025
Drug: ER2001 injection · For: Huntington Disease
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Huntington Disease
- SKY-0515Phase 33 trials
Skyhawk Therapeutics, Inc. · Huntington Disease, Huntingtons Disease, Huntington's Disease (HD)
- PridopidinePhase 32 trials
Prilenia · Amyotrophic Lateral Sclerosis, Huntington Disease
- MBF-015Phase 21 trial
Medibiofarma S.L. · Huntington Disease
- TominersenRO7234292, RG6042Phase 21 trial
Roche (Genentech) · Huntington Disease
- VO659Phase 21 trial
Vico Therapeutics B. V. · Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.